Take Solutions Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹6 Cr
QSept 2025
In Sept 2025, Take Solutions (TAKE) reported revenue ₹7 Cr and net profit ₹6 Cr. Compare with TAKE fair price to assess whether the stock is under or overvalued.
TAKE Quarterly Results — Revenue, Profit & EPS Highlights
Take Solutions latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore TAKE share price charts to track price trends across different timeframes.
- Revenue of ₹7 Cr in Sept 2025 (+250.0% vs Mar 2025)
- Net Profit of ₹6 Cr in Sept 2025 (+220.0% vs Mar 2025, +400.0% vs Sept 2024)
- EBITDA of ₹7 Cr in Sept 2025 (+240.0% vs Mar 2025)
- Earnings Per Share of ₹0.43 in Sept 2025 (+230.3% vs Mar 2025)
Take Solutions Quarterly Results — Revenue, EBITDA, Net Profit & EPS
TAKE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 7 | 2 | 0 | 2 | 0 | 250.0% | - |
| Net Profit (₹ Cr) | 6 | -5 | -1 | 1 | -2 | - | - |
| EBITDA (₹ Cr) | 7 | -5 | -1 | 1 | -1 | - | - |
| EPS (₹) | 0.43 | -0.33 | -0.06 | 0.07 | -0.11 | - | - |
| Operating Margin (%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | - |
TAKE Share Price Trend — 1-Year Movement Across Quarterly Results
Take Solutions 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit TAKE screener.
Revenue Trend (₹ Cr)
Dec 2025
2
Jun 2025
0
Mar 2025
2
Sept 2025
7
Net Profit Trend (₹ Cr)
Dec 2025
1
Jun 2025
-1
Mar 2025
-5
Sept 2025
6
Operating Margin Trend (%)
Dec 2025
0.0%
Jun 2025
0.0%
Mar 2025
0.0%
Sept 2025
0.0%
TAKE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Take Solutions latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1905.8 | 14,875 | 3,125 | +10.8% | - | 21.0% | 146.6 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6835.0 | 2,860 | 689 | +7.1% | - | 24.1% | 263.2 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹149,048.00 Cr | 4393.7 | 3,219 | 591 | +11.3% | - | 18.4% | 250.5 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1426.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 207.6 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1331.2 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 502.3 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores